Name: Recombinant Antibody Expression
Brand: Tsingke Biotech
SKU: 00306
Availability: InStock
Rating: 5 (1 reviews)

Advantages

Fast Turnaround

The comprehensive expression service platform connects design, synthesis, and purification processes

High Expression Yield

Selected high-expression strains and optimized vectors, coupled with a refined process system

High Throughput

Swiftly process up to 800 samples per run for efficient delivery

Service Details

Service Name	Expression system	Service Code	Volume	Turnaround time
Recombinant Antibody Expression Service Anti-dsDNA antibodies,single chain antibody fragmen, VHH-His, VHH-FC, Fab, etc.	HEK293/CHO	Tsingke-006-3	10 mL	1~2 weeks
		Tsingke-006-4	20 mL
		Tsingke-006-5	30 mL
		Tsingke-006-6	40 mL
		Tsingke-006-7	50 mL
		Tsingke-006-8	100 mL
		Tsingke-006-9	200 mL
		Tsingke-006-10	500 mL
		Tsingke-006-11	1000 mL
		Tsingke-006-12	>1 L

Deliverables

Delivery Standard

Purified antibodies;

COA Report(electronic);

Optional：Antibody gene in commercial vectors.

SDS-PAGE&SEC-HPLC >95%;

Endotoxin level <1 EU/mg.

FAQ

What does recombinant antibody expression deliver?

Delivery of COA report;

All obtained antibodies (quantity not guaranteed);

Constructed expression plasmids.

If you require delivery of mg or g level antibodies for small-scale trials at Tsingke, please request a price evaluation.

How can I improve the stability of antibodies?

Optimizing elution conditions: Gradually lower the pH from a high value; neutralize the purified sample in a timely manner; prepare and store the sample at low temperatures during the purification process; add protein protectants such as glycerol and Tween; when antibody concentration is high, dilute promptly to prevent high-concentration aggregation.

Recombinant antibody production makes the preparation of humanized and fully human antibodies possible. It is a key technology for the industrialization of monoclonal antibody drugs. Recombinant antibodies are widely used in immunodiagnosis, therapeutic antibodies, and other fields. Qingke Biotechnology has a comprehensive recombinant antibody expression production platform, rich experience in recombinant protein and recombinant antibody expression, and is capable of producing monoclonal antibodies for clients, including single-chain antibodies (scFv), single-domain antibodies, humanized antibodies, and Fc-fusion antibodies. The transient expression system uses CHO cells and HEK293 cells as expression hosts for suspension culture, and can produce recombinant antibodies from milligrams to kilograms.

What are the advantages of recombinant antibodies?

(1) Short production cycle: Recombinant antibodies can be produced in a few weeks, whereas hybridoma antibody production takes several months.

(2) High consistency and reproducibility: The genes of recombinant antibodies are defined, making the antibody production process controllable and reliable, resulting in minimal batch-to-batch variation and good reproducibility.

(3) High sensitivity and specificity: Gene engineering modifications and recombinant techniques enable the selection of higher-quality antibodies.

(4) Low immunogenicity: No need for immunization and screening.

(5) Large-scale antibody production: Enables animal-free production in vitro.

How can I improve the translation, modification, and secretion capacity of recombinant antibodies?

For most recombinant cells, translation, modification, and secretion are the rate-limiting steps in the biosynthesis of antibodies. Therefore, genetic manipulation of molecular chaperones involved in the biosynthesis of the target protein can enhance the recombinant antibody expression capacity of the host cells. Such molecular chaperones include protein disulfide isomerase, endoplasmic reticulum oxidoreductase, heavy chain-binding protein, ERp57, GRP94, and X-box binding protein 1 (XBP-1S), among others.

The glycosylation modification of antibodies significantly impacts their biological activity. By utilizing cell engineering techniques to modify the glycosylation capabilities of the host, the clinical efficacy of recombinant antibodies can be improved. For example, knocking out fucosyltransferase (FUT8) or overexpressing N-acetylglucosamine transferase (GnT-III) can reduce the fucose content in the glycan chains of recombinant antibodies, enhancing the antibody-dependent cellular cytotoxicity (ADCC) effect of antibody drugs. Overexpressing sialyltransferase can increase the sialic acid content of the antibody, improving its anti-inflammatory activity.